Drug Profile

Deferitazole

Alternative Names: Deferitazole magnesium; FBS-0701; SHP602; SPD-602; SSP-004184; SSP-004184AQ; SSP-004184SS

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator FerroKin BioSciences
Class Heterocyclic acids; Small molecules; Thiazoles
Mechanism of Action Iron chelating agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Iron overload
New Molecular Entity Yes

Highest Development Phases

Discontinued Iron overload

Most Recent Events

08 Jan 2019 Shire has been acquired and merged into Takeda
18 Mar 2014 Suspended - Phase-I for Iron overload in Australia (PO)
18 Mar 2014 Suspended - Phase-II for Iron overload in USA, Canada, Italy, Lebanon, Thailand, Turkey and United Kingdom before March 2014 (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com